COPD Therapeutics Market Size

COPD Therapeutics Market size was over USD 12.91 billion in 2024 and is poised to exceed USD 24.95 billion by 2037, witnessing over 5.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of COPD therapeutics is evaluated at USD 13.48 billion.

The growth of the market can be attributed primarily to the rising prevalence of chronic obstructive pulmonary disease (COPD) which is affecting millions of people worldwide. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third most common cause of death worldwide, which accounted for 3.23 million deaths in 2019. About 90% of COPD deaths among those under the age of 70 years are associated with low- and middle-income countries. As a result of increasing burden of this disease, the global COPD therapeutics market size is expected to enlarge during the forecast period.

Chronic obstructive pulmonary disease is obstructive pulmonary diseases that affect the lungs and cause breathing difficulty and excessive coughing. The two most common types of COPD are chronic bronchitis and emphysema. The diseases can damage parts of the lungs, block airways with mucus, and cause soreness and inflammation. In addition, increasing cases of asthma worldwide are expected to drive the global COPD therapeutics market. As per the data by the World Health Organization, a total of 262 million people were affected by asthma in 2019 and 455 000 people died from it. Asthma is a chronic inflammatory lung disease that affects the airways and is primarily caused by allergies, irritants, cold air, and dust. Airborne allergens, irritants, extreme weather conditions, harmful gases, chemicals, multiple lower respiratory infections in childhood, and an unhealthy lifestyle are all expected to drive the global COPD therapeutics market. Moreover, global COPD therapeutics market trends such as increasing utilization of digital inhalers and Combination therapy treatment such as LAMA-ICS, LABA-ICS, and triple therapy are projected to drive market growth during the forecast period.